Application and progress of artificial intelligence in the evaluation of anti-VEGF therapy for retinopathy of prematurity
10.3760/cma.j.cn115989-20230923-00109
- VernacularTitle:人工智能在评估抗VEGF治疗早产儿视网膜病变中的应用研究进展
- Author:
Weiwei LING
1
;
Yanyan ZHANG
;
Quanyong YI
Author Information
1. 宁波大学医学部，宁波 315211
- Publication Type:Journal Article
- Keywords:
Artificial intelligence;
Retinopathy of prematurity;
Anti-vascular endothelial growth factor
- From:
Chinese Journal of Experimental Ophthalmology
2025;43(11):1060-1064
- CountryChina
- Language:Chinese
-
Abstract:
Retinopathy of prematurity (ROP) is a type of proliferative retinal disease occurring in premature, low birth weight infants, and is one of the most common blinding diseases in infants and young children.In recent years, anti-vascular endothelial growth factor (VEGF) therapy has shown good effect in treating ROP, and has become the preferred treatment for some ROP.However, the anti-VEGF treatment of ROP still faces the bottleneck of uncertain treatment timing and lack of objective criteria for efficacy evaluation.In recent years, artificial intelligence (AI) has not only been widely used in the screening and diagnosis of ROP, but also has made progress in evaluating treatment timing, therapeutic effect and follow-up plan in anti-VEGF treatment of ROP.At the same time, AI also shows potential in the prediction of efficacy and disease progression after anti-VEGF treatment of ROP.Therefore, based on recent relevant studies at home and abroad, this article reviews and looks forward to the application of AI in the evaluation of anti-VEGF treatment of ROP.
